Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …

Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …

Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …

Observational studies and stand-alone trials indicate that patients with follicular lymphoma
(FL) who experience disease progression within 24 months of front-line …

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most
common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of …

Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …

An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and
high-risk disease features, such as progression of disease within 24 months (POD24) from …

Patients undergoing evaluation for solid organ transplantation (SOT) frequently have a
history of malignancy. Only patients with treated cancer are considered for SOT but the …

Follicular lymphoma, the most common indolent lymphoma, though highly responsive to
therapy is coupled with multiple relapses for the majority of patients. Advances in biologic …